OptiBiotix surges as SlimBiome granted CE mark and medical device status

Close up of hands and stationery, showing business people on a calculator

OptiBiotix surges as SlimBiome granted CE mark and medical device status

Shares in OptiBiotix Health plc surged in early trading Tuesday after its SlimBiome weight loss product received a CE mark as well as medical device status.

The CE mark allows the product to be freely marketed within the European Economic Area (EEA), as well as providing eligibility for shortened medical product registration procedures in other markets such as China and the United Arab Emirates.

See article in full at ProactiveInvestors.co.uk

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.